Roswell Park Comprehensive Cancer Center

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

Retrieved on: 
월요일, 1월 10, 2022
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, Roswell Park Comprehensive Cancer Center, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Cell cycle, COVID-19, Corner, Joint venture, Knowledge, Synthase, TBIA, Plasma, GLOBE, Solution, Lymphocyte, Cancer, The Claman Countdown, NLC, Acquisition, Monocyte, Company, Method, Blog, Neuron, Immune system, TMB-2, Pressure, International joint venture, Todos, Brain, Everything That Happens Will Happen Today, Alzheimer's disease, COVID, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Jan. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will appear on Fox Business’ The Claman Countdown on Tuesday, January 11 during the 3pm Eastern Time hour show to discuss COVID testing in the United States and how it relates to the pending availability of oral antiviral treatments such as the Company’s Tollovir™ 3CL protease inhibitor oral antiviral treatment currently preparing to read out on Phase 2 clinical data in hospitalized patients. Mr. Commissiong is also presenting at the Biotech Showcase 2022 to be held virtually from January 10-12th, 2022. Concurrent with this announcement, Mr. Commissiong released a blog entitled “COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” that discusses key points needed to improve the United States COVID testing infrastructure. The blog posting is available online at https://todosmedical.com/blog/covid-testing-what-needs-to-happen-now-to-....

Key Points: 
  • Mr. Commissiong is also presenting at the Biotech Showcase 2022 to be held virtually from January 10-12th, 2022.
  • Please follow the Companys Twitter account for any updates to the time: https://twitter.com/todosmedical
    Registered attendees to Biotech Showcase can access Todos Medicals pre-recorded company presentation prior to the event.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States.

Hibiscus BioVentures Partners with the Barbara Ann Karmanos Cancer Institute to Advance Translational Cancer Research

Retrieved on: 
수요일, 1월 5, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Karmanos Cancer Institute, University, Courage, FACP, Health, Therapy, NCI, Research, Education, McLaren Health Care Corporation, Clinical and Translational Science Award, Patient, Wayne, Organization, Cancer, Wayne State University, Science, Roswell Park Comprehensive Cancer Center, National Cancer Institute, Venture capital, Hope, CEO, MD, Partnership, Multimedia, Biotechnology, Leadership, National, Pharmaceutical industry, Hibiscus, Karmanos

Hibiscus BioVentures , a firm committed to building patient-focused companies around transformative technologies, today announced it has entered into a partnership agreement with the Detroit-based Barbara Ann Karmanos Cancer Institute (Karmanos).

Key Points: 
  • Hibiscus BioVentures , a firm committed to building patient-focused companies around transformative technologies, today announced it has entered into a partnership agreement with the Detroit-based Barbara Ann Karmanos Cancer Institute (Karmanos).
  • Karmanos is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the country.
  • As translational and clinical research partners, this collaboration is focused on combining programs, capabilities and infrastructure from Hibiscus Biotechnologys Studio Companies with Karmanos vast clinical research and development resources to advance cancer therapies and address unmet patient needs.
  • The Barbara Ann Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment, and compassion.

Protecting People with Cancer from COVID-19: New Recommendations from Cancer Guidelines Organization

Retrieved on: 
화요일, 1월 4, 2022
Immunodeficiency, Caregiver, HCT, Face, Policy, AB, COVID-19, Roswell Park Comprehensive Cancer Center, Hospital, Vaccine, NCCN, Food, RNA transfection, DiGeorge syndrome, Health, Review, Research, Education, Patient, Journal of the National Comprehensive Cancer Network, Vaccination, Stem cell, Cancer, Infection, National Comprehensive Cancer Network, Transplant, Food and Drug Administration, Twitter, Wiskott–Aldrich syndrome, ASH, Society, HIV, Decision-making, Medicine, FDA, Lymphatic system, Pre-exposure prophylaxis, Centers for Disease Control and Prevention, Center, Risk, CAR, Haematopoietic system, Death, CDC, Pharmaceutical industry, Medical device, MD

PLYMOUTH MEETING, Pa., Jan. 4, 2022 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) published significant updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer. The NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis meets frequently to review all available research and provide evidence-based best practices for keeping people with cancer as safe as possible during the COVID-19 pandemic. The updated guidance—available at NCCN.org/covid-19—includes information on the preventive use of human monoclonal antibodies in addition to the following principals:

Key Points: 
  • Vaccine delays in patients with cancer should also include those recommended for the general public (e.g.
  • Thankfully, we now have additional tools to help people in active treatment for cancer, solid organ transplant recipients, engineered cellular therapy (e.g.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing

Retrieved on: 
목요일, 12월 23, 2021
U.S. Securities and Exchange Commission, International joint venture, Technology, TMB-2, Legislation, Knowledge, Neurodegeneration, Patient, Neuron, Emergency Use Authorization, Cancer, Alzheimer's disease, CEO, NLC, Cell cycle, Roswell Park Comprehensive Cancer Center, TBIA, OTCQB, Method, Acquisition, Pressure, COVID-19, Solution, PCR, Synthase, Brain, Immune system, Biotechnology, Monocyte, Lymphocyte, COVID, Company, Plasma, Apoptosis, Research, BNC, GLOBE, Todos, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Yahoo Finance Live with Akiko Fujita at 12:10 PM Eastern Time today. Mr. Commissiong will discuss the current state of COVID testing as well as emerging COVID antiviral pills, including Pfizer’s Paxlovid that recently received Emergency Use Authorization for the At-Home Treatment of mild to moderate COVID-19, and the Company’s Tollovir™ for hospitalized COVID patients.

Key Points: 
  • The segment can also be viewed online at: https://finance.yahoo.com/
    Mr. Commissiong will also appear on BNC at 1:50PM EST to discuss the recent authorization of Pfizers COVID antiviral drug, Paxlovid, and the Companys Phase 2 oral antiviral Tollovir.
  • For more information on Provistas parent company Todos Medical, please visit www.todosmedical.com .
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.

Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing

Retrieved on: 
월요일, 12월 20, 2021
Omni, Alzheimer's disease, Severe acute respiratory syndrome coronavirus 2, Acquisition, Lymphocyte, TMB-2, TBIA, Synthase, MBA, Legislation, WebMD, International joint venture, Solution, PCR, Cancer, Growth, Monocyte, Plasma, Brick, Long Island University, GLOBE, U.S. Securities and Exchange Commission, NLC, OTC, OTCQB, Roswell Park Comprehensive Cancer Center, Neurodegeneration, Global marketing, COVID-19, CEO, Research, Marketing, Biotechnology, TEL, Associate, Apoptosis, Method, Pressure, Omicron, COVID, Staten Island University Hospital, Company, Brain, United, Medical Affairs Bureau, Patient, Knowledge, Immune system, Neuron, Technology, Cell cycle, Pharmaceutical industry, Medical imaging, Merck, Todos, Novartis

NEW YORK, NY and TEL AVIV, Israel , Dec. 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has appointed Mr. Valentino Smith, MBA as Vice President of Marketing.

Key Points: 
  • NEW YORK, NY and TEL AVIV, Israel , Dec. 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has appointed Mr. Valentino Smith, MBA as Vice President of Marketing.
  • Mr. Valentino joins Todos with over 10 years of marketing experience in healthcare.
  • Mr. Valentino is currently an Adjunct Assistant Professor of Marketing at Long Island University and received his undergraduate and MBA degrees from Long Island University.
  • We are very excited to be partnering with Todos Medical on the pending marketing campaigns for Tollovid and Tollovid Daily, said Chase Gibson, Co-CEO of iiiNTENT.

CYCLE FOR SURVIVAL LAUNCHES 2022 EVENTS WITH OUTDOOR RIDES

Retrieved on: 
목요일, 12월 16, 2021
Survivor, Cancer, Roswell Park Comprehensive Cancer Center, YORK, Lymphoma, Lead, Cycle for Survival, Instagram, Physician, Adult, Wild, National Cancer Institute, Wollman Rink, LIFE, Memorial Sloan Kettering Cancer Center, Hudson Yards, MD, GLOBE, City, Health, Nursing, CEO, Research, Leukemia, YouTube, Twitter, Regeneration, Club, Equinox Group, Brain, Daily, Yoga, Caregiver, MSK, Patient, Survival, The Wild, Birth control, Pharmaceutical industry, Equinox, Facebook, Cycle, Movement

Renowned instructors from Equinox Group, Cycle for Survivals founding partner, will lead the high-energy team events.

Key Points: 
  • Renowned instructors from Equinox Group, Cycle for Survivals founding partner, will lead the high-energy team events.
  • Since it was founded in 2007, Cycle for Survival has raised $286 million, with $180 million raised in the past five years.
  • 100 percent of every dollar funds groundbreaking rare cancer research at Memorial Sloan Kettering Cancer Center (MSK), which owns and operates Cycle for Survival.
  • In addition to the outdoor rides, Cycle for Survival will offer a special virtual event.

EPIC SCIENCES UNVEILS DefineMBC™, A NOVEL BLOOD-BASED TEST DESIGNED TO IMPROVE CARE FOR METASTATIC BREAST CANCER PATIENTS

Retrieved on: 
목요일, 12월 16, 2021
HER2, CTC, Medi-Cal Access Program, NGS, Physician, Cancer, Cell, Diagnosis, Health, SAN, Nucleic acid thermodynamics, MSI, Breast cancer, TMB, CNV, Prostate, Roswell Park Comprehensive Cancer Center, CEO, Research, Gene, Machine learning, Patient, Neoplasm, Drug development, Microsatellite instability, Chinese, Liquid biopsy, DNA, ER, MBC, SNV calling from NGS data, Epic Sciences, Medical imaging

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.

Key Points: 
  • SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.
  • DefineMBC uses both cell-based and cell-free analysis from a simple blood draw and provides information for optimal treatment decision making," says Rick Wenstrup MD, Chief Medical Officer, Epic Sciences.
  • Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancer.
  • Using its full-service CLIA/CAP accredited laboratory and research support services in San Diego, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual Meeting

Retrieved on: 
일요일, 12월 12, 2021
Multiple myeloma, Doctor of Philosophy, Standard of care, Degenerative disease, Aggression, Lymphatic system, Azacitidine, Assistant, Memorial Sloan Kettering Cancer Center, National Cancer Institute, Society, University, MDS, Mutation, Department, Graft-versus-host disease, Hope, Myelodysplastic syndrome, Adult, Upstate New York, Pharmacology, MD, Trial of the century, Bleeding, Immunotherapy, FLT3, Patient, CAR, Sung, Lymphoma, DVM, B-cell lymphoma, ASH, Leukemia, Safety, Research, AML, EZH2, Vaccine, Pharmaceutical industry, Medicine, Roswell Park Comprehensive Cancer Center

BUFFALO, N.Y., Dec. 11, 2021 /PRNewswire-PRWeb/ --Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia.

Key Points: 
  • BUFFALO, N.Y., Dec. 11, 2021 /PRNewswire-PRWeb/ --Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia.
  • The many research projects to be highlighted include breakthrough research on CAR T cell therapy, immunotherapy, leukemia, lymphoma and the management of genetic mutations in aggressive and rare blood cancers.
  • On Monday, Dec. 13, two Roswell Park specialists in FLT3-mutated acute myeloid leukemia (AML) will present study findings that could shape the treatment of this rapidly progressing cancer.
  • Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.

Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST

Retrieved on: 
금요일, 12월 10, 2021
Solution, Interview, Apoptosis, Technology, U.S. Securities and Exchange Commission, Knowledge, Todos, All Access, Brain, Synthase, Roswell Park Comprehensive Cancer Center, COVID-19, Pressure, Cancer, Legislation, Method, Patient, Conference, Neurodegeneration, PCR, TBIA, GLOBE, Webcast, Immune system, Cell cycle, Company, Biotechnology, Neuron, International joint venture, Monocyte, Research, OTCQB, TMB-2, NLC, Plasma, Acquisition, Lymphocyte, Alzheimer's disease, Pharmaceutical industry, Medical imaging

Benzinga All Access is a first-of-its-kind show which consists of part interview and part investor presentation.

Key Points: 
  • Benzinga All Access is a first-of-its-kind show which consists of part interview and part investor presentation.
  • On All Access, Benzinga partners with companies to bring in-depth one-on-one conversations with executives across a wide range of industries and asset classes.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.

EPIC sciences platform Demonstrates compelling Value of Cell Analysis in data Presented AT San Antonio Breast Cancer Symposium 2021

Retrieved on: 
수요일, 12월 8, 2021
Blood, Epic Sciences, Research, Texas Oncology, Oncology, CTC, Patient, Breast cancer, CEO, Neoplasm, Prostate, Roswell Park Comprehensive Cancer Center, Woman, Baylor University Medical Center, Survival, SAN, Medical imaging

SAN DIEGO, Dec. 8, 2021 /PRNewswire/ --Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.

Key Points: 
  • SAN DIEGO, Dec. 8, 2021 /PRNewswire/ --Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.
  • Since 2018, the Epic platform has been providing clinically validated predictive information about selective hormone therapy resistance for patients with metastatic prostate cancer.
  • Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancer.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.